nodes	percent_of_prediction	percent_of_DWPC	metapath
Famotidine—Sinus disorder—Hydrochlorothiazide—nephrolithiasis	0.074	0.16	CcSEcCtD
Famotidine—Knee pain—Hydrochlorothiazide—nephrolithiasis	0.074	0.16	CcSEcCtD
Famotidine—SLC22A8—Organic anion transport—SLC22A12—nephrolithiasis	0.0584	0.175	CbGpPWpGaD
Famotidine—Anxiety disorder—Hydrochlorothiazide—nephrolithiasis	0.0451	0.0975	CcSEcCtD
Famotidine—SLC22A2—nephron—nephrolithiasis	0.0447	0.219	CbGeAlD
Famotidine—SLC22A8—nephron—nephrolithiasis	0.029	0.142	CbGeAlD
Famotidine—SLC22A8—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.0272	0.0815	CbGpPWpGaD
Famotidine—SLC22A8—urine—nephrolithiasis	0.0233	0.114	CbGeAlD
Famotidine—CYP2C19—urine—nephrolithiasis	0.0195	0.0956	CbGeAlD
Famotidine—SLC22A2—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.0189	0.0567	CbGpPWpGaD
Famotidine—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.0116	0.0346	CbGpPWpGaD
Famotidine—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.0107	0.0322	CbGpPWpGaD
Famotidine—SLC22A2—nephron tubule—nephrolithiasis	0.00965	0.0472	CbGeAlD
Famotidine—HRH2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00952	0.0285	CbGpPWpGaD
Famotidine—SLC22A2—renal system—nephrolithiasis	0.00877	0.0429	CbGeAlD
Famotidine—SLC22A2—kidney—nephrolithiasis	0.00848	0.0415	CbGeAlD
Famotidine—SLC22A2—cortex of kidney—nephrolithiasis	0.00826	0.0404	CbGeAlD
Famotidine—SLC47A1—nephron tubule—nephrolithiasis	0.00817	0.04	CbGeAlD
Famotidine—HRH2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.008	0.024	CbGpPWpGaD
Famotidine—Jaundice cholestatic—Hydrochlorothiazide—nephrolithiasis	0.00794	0.0172	CcSEcCtD
Famotidine—Rhabdomyolysis—Hydrochlorothiazide—nephrolithiasis	0.00788	0.0171	CcSEcCtD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00757	0.0227	CbGpPWpGaD
Famotidine—SLC47A1—renal system—nephrolithiasis	0.00743	0.0364	CbGeAlD
Famotidine—SLC47A1—kidney—nephrolithiasis	0.00718	0.0351	CbGeAlD
Famotidine—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00706	0.0153	CcSEcCtD
Famotidine—SLC47A1—cortex of kidney—nephrolithiasis	0.00699	0.0342	CbGeAlD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00693	0.0208	CbGpPWpGaD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00693	0.0208	CbGpPWpGaD
Famotidine—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.00677	0.0147	CcSEcCtD
Famotidine—SLC22A8—nephron tubule—nephrolithiasis	0.00627	0.0307	CbGeAlD
Famotidine—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.00576	0.0125	CcSEcCtD
Famotidine—Swelling—Hydrochlorothiazide—nephrolithiasis	0.00574	0.0124	CcSEcCtD
Famotidine—SLC22A8—renal system—nephrolithiasis	0.0057	0.0279	CbGeAlD
Famotidine—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.00556	0.012	CcSEcCtD
Famotidine—SLC22A8—kidney—nephrolithiasis	0.00551	0.027	CbGeAlD
Famotidine—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00546	0.0118	CcSEcCtD
Famotidine—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00544	0.0163	CbGpPWpGaD
Famotidine—SLC22A8—cortex of kidney—nephrolithiasis	0.00536	0.0263	CbGeAlD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00525	0.0157	CbGpPWpGaD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00525	0.0157	CbGpPWpGaD
Famotidine—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00506	0.011	CcSEcCtD
Famotidine—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00506	0.0152	CbGpPWpGaD
Famotidine—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00502	0.0109	CcSEcCtD
Famotidine—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00498	0.0108	CcSEcCtD
Famotidine—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00489	0.0106	CcSEcCtD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00488	0.0146	CbGpPWpGaD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00488	0.0146	CbGpPWpGaD
Famotidine—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00464	0.01	CcSEcCtD
Famotidine—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00456	0.00986	CcSEcCtD
Famotidine—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00456	0.00986	CcSEcCtD
Famotidine—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00456	0.00986	CcSEcCtD
Famotidine—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00437	0.00947	CcSEcCtD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00435	0.013	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00432	0.0129	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00432	0.0129	CbGpPWpGaD
Famotidine—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00409	0.00885	CcSEcCtD
Famotidine—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00409	0.00885	CcSEcCtD
Famotidine—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00407	0.0088	CcSEcCtD
Famotidine—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00404	0.00874	CcSEcCtD
Famotidine—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00403	0.00872	CcSEcCtD
Famotidine—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00399	0.00864	CcSEcCtD
Famotidine—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00387	0.00837	CcSEcCtD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00385	0.0115	CbGpPWpGaD
Famotidine—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.0038	0.00823	CcSEcCtD
Famotidine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00379	0.0114	CbGpPWpGaD
Famotidine—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00372	0.00805	CcSEcCtD
Famotidine—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00366	0.00792	CcSEcCtD
Famotidine—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00364	0.00788	CcSEcCtD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00357	0.0107	CbGpPWpGaD
Famotidine—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00356	0.00771	CcSEcCtD
Famotidine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00352	0.0106	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00352	0.0106	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00352	0.0106	CbGpPWpGaD
Famotidine—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.0035	0.00758	CcSEcCtD
Famotidine—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00348	0.00752	CcSEcCtD
Famotidine—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00331	0.00716	CcSEcCtD
Famotidine—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00326	0.00706	CcSEcCtD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00326	0.00979	CbGpPWpGaD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00326	0.00979	CbGpPWpGaD
Famotidine—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00325	0.00703	CcSEcCtD
Famotidine—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00313	0.00677	CcSEcCtD
Famotidine—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00309	0.0067	CcSEcCtD
Famotidine—HRH2—G alpha (s) signalling events—PTH—nephrolithiasis	0.00302	0.00905	CbGpPWpGaD
Famotidine—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00299	0.00646	CcSEcCtD
Famotidine—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00295	0.00638	CcSEcCtD
Famotidine—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00293	0.00634	CcSEcCtD
Famotidine—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00282	0.0061	CcSEcCtD
Famotidine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.0028	0.00606	CcSEcCtD
Famotidine—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00279	0.00603	CcSEcCtD
Famotidine—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00273	0.00592	CcSEcCtD
Famotidine—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00273	0.0059	CcSEcCtD
Famotidine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00269	0.00583	CcSEcCtD
Famotidine—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00268	0.0058	CcSEcCtD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00267	0.008	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00267	0.008	CbGpPWpGaD
Famotidine—Cough—Hydrochlorothiazide—nephrolithiasis	0.00266	0.00576	CcSEcCtD
Famotidine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.0026	0.00562	CcSEcCtD
Famotidine—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.0026	0.00562	CcSEcCtD
Famotidine—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.0026	0.00562	CcSEcCtD
Famotidine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00259	0.0056	CcSEcCtD
Famotidine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00254	0.00549	CcSEcCtD
Famotidine—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00251	0.00543	CcSEcCtD
Famotidine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00249	0.00538	CcSEcCtD
Famotidine—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00249	0.00538	CcSEcCtD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00248	0.00744	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00248	0.00744	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00248	0.00744	CbGpPWpGaD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00247	0.00742	CbGpPWpGaD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00247	0.00742	CbGpPWpGaD
Famotidine—Shock—Hydrochlorothiazide—nephrolithiasis	0.00245	0.0053	CcSEcCtD
Famotidine—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00244	0.00527	CcSEcCtD
Famotidine—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00237	0.00513	CcSEcCtD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.0023	0.00689	CbGpPWpGaD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.0023	0.00689	CbGpPWpGaD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00227	0.00681	CbGpPWpGaD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00227	0.00681	CbGpPWpGaD
Famotidine—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00227	0.0049	CcSEcCtD
Famotidine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00225	0.00487	CcSEcCtD
Famotidine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00223	0.00483	CcSEcCtD
Famotidine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00221	0.00479	CcSEcCtD
Famotidine—SLC47A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00221	0.00663	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00221	0.00663	CbGpPWpGaD
Famotidine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00219	0.00474	CcSEcCtD
Famotidine—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00216	0.00468	CcSEcCtD
Famotidine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00214	0.00464	CcSEcCtD
Famotidine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00213	0.0046	CcSEcCtD
Famotidine—Pain—Hydrochlorothiazide—nephrolithiasis	0.00213	0.0046	CcSEcCtD
Famotidine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00444	CcSEcCtD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00205	0.00615	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00203	0.0061	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00203	0.0061	CbGpPWpGaD
Famotidine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00203	0.0044	CcSEcCtD
Famotidine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00198	0.00428	CcSEcCtD
Famotidine—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00197	0.00426	CcSEcCtD
Famotidine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00197	0.00426	CcSEcCtD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00184	0.00551	CbGpPWpGaD
Famotidine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00183	0.00397	CcSEcCtD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00181	0.00544	CbGpPWpGaD
Famotidine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00178	0.00386	CcSEcCtD
Famotidine—SLC47A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00177	0.0053	CbGpPWpGaD
Famotidine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00176	0.00381	CcSEcCtD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00172	0.00516	CbGpPWpGaD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00172	0.00516	CbGpPWpGaD
Famotidine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.0017	0.00368	CcSEcCtD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00166	0.00497	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00166	0.00497	CbGpPWpGaD
Famotidine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00165	0.00356	CcSEcCtD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.0016	0.0048	CbGpPWpGaD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.0016	0.0048	CbGpPWpGaD
Famotidine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00158	0.00342	CcSEcCtD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00157	0.00472	CbGpPWpGaD
Famotidine—Rash—Hydrochlorothiazide—nephrolithiasis	0.00157	0.00339	CcSEcCtD
Famotidine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00157	0.00339	CcSEcCtD
Famotidine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00156	0.00337	CcSEcCtD
Famotidine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00148	0.0032	CcSEcCtD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00143	0.00428	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00142	0.00424	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00142	0.00424	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—RGS14—nephrolithiasis	0.00139	0.00416	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00126	0.00378	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—RGS14—nephrolithiasis	0.00126	0.00378	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00126	0.00377	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00126	0.00377	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.00125	0.00374	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CHRM3—nephrolithiasis	0.0012	0.00359	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00117	0.0035	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00117	0.0035	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00115	0.00346	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00115	0.00346	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—PTH—nephrolithiasis	0.0011	0.00329	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00104	0.00312	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00104	0.00312	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000937	0.00281	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ADCY10—nephrolithiasis	0.000875	0.00262	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000875	0.00262	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000875	0.00262	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—DGKH—nephrolithiasis	0.000851	0.00255	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000833	0.0025	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000813	0.00244	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000813	0.00244	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—RGS14—nephrolithiasis	0.000744	0.00223	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000725	0.00217	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000725	0.00217	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000677	0.00203	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PTH—nephrolithiasis	0.000619	0.00186	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CHRM3—nephrolithiasis	0.000615	0.00184	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000579	0.00174	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PTH—nephrolithiasis	0.000563	0.00169	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000503	0.00151	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—DGKH—nephrolithiasis	0.000503	0.00151	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GRHPR—nephrolithiasis	0.000503	0.00151	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—AGXT—nephrolithiasis	0.000448	0.00134	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SLC26A1—nephrolithiasis	0.000381	0.00114	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—APRT—nephrolithiasis	0.000381	0.00114	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CHRM3—nephrolithiasis	0.000363	0.00109	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PTH—nephrolithiasis	0.000332	0.000996	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GRHPR—nephrolithiasis	0.000281	0.000843	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—AQP1—nephrolithiasis	0.000271	0.000814	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—AGXT—nephrolithiasis	0.000251	0.000752	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CHRM3—nephrolithiasis	0.000245	0.000736	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—APRT—nephrolithiasis	0.000213	0.000639	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	0.000213	0.000639	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SPP1—nephrolithiasis	0.000167	0.0005	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—AQP1—nephrolithiasis	0.000152	0.000455	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CHRM3—nephrolithiasis	0.000137	0.000412	CbGpPWpGaD
